tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Oruka Therapeutics’ ORKA-001: Promising Developments and Buy Rating Justification
PremiumRatingsOruka Therapeutics’ ORKA-001: Promising Developments and Buy Rating Justification
3M ago
Oruka Therapeutics Reports Strong 2024 Financial Results
Premium
Company Announcements
Oruka Therapeutics Reports Strong 2024 Financial Results
4M ago
Oruka Therapeutics at Risk: Navigating Licensing Challenges and Partner Reliance
Premium
Company Announcements
Oruka Therapeutics at Risk: Navigating Licensing Challenges and Partner Reliance
5M ago
Oruka Therapeutics Positioned for Growth with Strategic Licensing and Promising IL-17A/F Inhibitor Development
PremiumRatingsOruka Therapeutics Positioned for Growth with Strategic Licensing and Promising IL-17A/F Inhibitor Development
6M ago
Oruka Therapeutics initiated with an Outperform at Wolfe Research
Premium
The Fly
Oruka Therapeutics initiated with an Outperform at Wolfe Research
6M ago
Oruka Therapeutics initiated with an Outperform at Wolfe Research
Premium
The Fly
Oruka Therapeutics initiated with an Outperform at Wolfe Research
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100